Clinical Trial

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The purpose of this study is to assess the safety and efficacy of using lean body mass (LBM) to determine pump flow rate and/or Heparin dosage in obese patients undergoing CPB.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-10-03; most recent amendment 2023-03-09.
Trial Details
NCT Number NCT03302195
Lead Sponsor Laval University
Collaborators: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Conditions Cardiopulmonary Bypass, Obesity
Enrollment 410 participants
Start Date 2015-08-21
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-03-10